Drugs
(XML - 11KB)Current Drug Shortages O - R
The information provided in this section is provided voluntarily by manufacturers. FDA cannot require firms to report the reason for shortage or duration of the shortage or any other information about shortages. FDA appreciates all information provided by manufacturers. We post information about shortages as soon as we receive it from the manufacturers. To report information about shortages or supply issues, manufacturers can send updates to drugshortages@fda.hhs.gov. Healthcare professionals and patients are also encouraged to notify us of shortages at drugshortages@fda.hhs.gov.
*Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012
**Listed by Generic name or Active Ingredient**
Ondansetron (Zofran) Injection 2 mg/mL
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
APP | 4 mg; 2 mL (NDC 63323-0373-02) | Available Check wholesalers for inventory. | APP currently has both presentations of Ondansetron available. Please check wholesalers for inventory.
Shortage per Manufacturer: | Demand increase for the drug. | Reverified 2/19/2013 |
| 40 mg; 20 mL (NDC 63323-0374-20) | Available Check wholesalers for inventory. | ||||
Bedford 20 mL vial (NDC 55390-0121-01) | 2 mL vials, packages of 10 (NDC 55390-0121-10) - discontinued | Bedford has ondansetron 2 mg/mL 20 mL vials on back order and the company cannot estimate a release date. Bedford Laboratories has multiple products affected by this temporary suspension of manufacturing. Bedford will have the affected, as well as the available products, listed on their website and are updating this information as it changes. The company voluntarily suspended all manufacturing and distribution in mid-November, 2011 on a temporary basis for maintenance and requalification of equipment. Product will become available in stages as production resumes. Bedford discontinued the following products: Shortage per Manufacturer: | Discontinuation of the manufacture of the drug. | ||
| 2 mL Novaplus vials, packages of 10 (NDC 55390-0307-10) - discontinued | |||||
| 20 mL Novaplus vials, packages of 1 (NDC 55390-0307-01) - discontinued | |||||
| Caraco 313-871-8400 | 2 mL ampules (NDC 62756-0181-01) | Caraco temporarily discontinued ondansetron injection | Discontinuation of the manufacture of the drug. | ||
| 20 mL vials (NDC 62756-0182-01) | |||||
| Hospira, Inc. Customer Service: 1-877-946-7747 | 2 mg/mL; 2 mL vials (NDC 0409-4755-03) | Next delivery mid February Estimated recovery 3Q 2013 | Please check with your wholesaler for available inventory. | Demand increase for the drug. | Revised 2/21/2013 |
| 2 mg/mL; 20 mL vials (NDC 0409-4759-01) | Next delivery April Estimated recovery: 1Q 2013 | ||||
| West-Ward (formerly Baxter products) Customer Service: | 2 mg/mL, 2 mL vial (NDC 0641-6078-25) | West-Ward has limited quantities available for both presentations. West-Ward has accelerated production on this product. | West-Ward has increased production and is anticipating having additional product available in the March 2013 timeframe. | Demand increase for the drug. | Revised 2/11/2013 |
2 mg/mL, 20 mL Vial (0641-6079-01) | |||||
| Teva 1-800-545-8800 | 20 mL vials (NDC 00703-7226-01) | Teva has inventory available. | Demand increase for the drug | Revised 3/1/2013 | |
| 20 mL vials (NDC 00703-7226-03) | |||||
| 2 mL vials (NDC 00703-7221-04) | |||||
| GlaxoSmithKline Customer Service: 1-888-825-5249 | Zofran injection, 2 mg/mL, 2 mL vials, packages of 5 (NDC 00173-00442-02) | GlaxoSmithKline has the following available: 20 mL vial (NDC 00173-0442-00) GlaxoSmithKline has discontinued Zofran 2 mL vials | Demand increase for the drug. | ||
| 20 mL vial (NDC 00173-0442-00) | |||||
| Wockhardt Customer Service: 1-800-346-6854 | 2 mg/mL, 2 mL vials, package of 5 (NDC 64679-0726-01) | Wockhardt has existing inventories and no backorder presently | Available | Demand increase for the drug. | Reverified 2/12/2013 |
| 2 mg/mL, 20 mL vials, package of 1 (NDC 64679-0727-01) | |||||
Pfizer
| Ondansetron 4 mg/2mL x 25 count (preservative fee, latex free) NDC 0069-1340-16 | Limited supply | Delay in shipping of the drug. | Reverified 2/25/2013 | |
| 40mg/20mL x 1 MDV NDC 0069-1340-02 | |||||
Sagent Pharmaceuticals 1-866-625-1618
| 2 mg/mL 2mL vial (NDC 25021-777-02) | Available | Reverified 2/18/2013 | ||
| 2mg/mL 20mL vial (NDC 25021-782-20) | Available | Demand Increase |
Ondansetron Injection 32 mg/50 mL premixed bags
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Claris | 32 mg/50 mL (NDC 36000-0014-06) | Pending information Shortage per Manufacturer:
| Other | ||
| Sagent Pharmaceuticals 1-866-625-1618 | 32 mg/50 mL (NDC 25021-0776-50) - discontinued | Sagent has discontinued their ondansetron premixed bags. | Shortage per Manufacturer: Discontinued | Discontinuation of the manufacture of the drug. | Reverified 1/28/2013 |
| Teva Pharmaceuticals 1-800-545-8800 | 32 mg/50 mL (NDC 00703-7239-39) | Teva has voluntarily withdrawn their application for this product. |
| Discontinuation of the manufacture of the drug. | Reverified 3/1/2013 |
| Hospira, Inc. Customer Service: 1-877-946-7747 | 0.64 mg/mL; 50 mL bag (32 mg/50 mL) (NDC 0409-4760-24) | Product is discontinued | Product discontinued due to FDA Drug Safety Communication | Discontinuation of the manufacture of the drug | Reverified 2/21/2013 |
| Baxter Customer Service: 1-888-229-0001 | Ondansetron Injection 32 mg/50 mL premixed bags (NDC 00338-1762-41) | Baxter has issued a voluntary recall and discontinued the manufacture and sale of this product. | New safety information communicated in the FDA Drug Safety Communication issued 06/29/2012 | Discontinuation of the manufacture of the drug | Reverified 2/28/2013 |
Oseltamivir Phosphate (Tamiflu) for Oral Suspension (6mg/mL, 60 mL) (Initial Posting Date) – 1/10/2013
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
Genentech, Inc.
Product support and fulfillment: 1-800-551-2231
Medical information: 1-800-821-8590 | Oral Suspension 6 mg/mL 60 mL (NDC 00004-0820-09) | Genentech has Tamiflu for Oral Suspension on intermittent backorder, however supplies remain in distribution at wholesalers and pharmacies. | Tamiflu 30 mg, 45 mg and 75 mg capsules remain available. Pediatric patients over 1 year of age can be dosed correctly using the 30 mg and 45 mg capsules.
For those patients who cannot swallow capsules, the capsules can be opened and the contents may be mixed with chocolate syrup or some other thick, sweet liquid, as directed by a healthcare professional.
If there is difficulty locating commercial Tamiflu for Oral Suspension, FDA would like to remind healthcare professionals of the FDA-approved Instructions for the emergency compounding of an oral suspension from Tamiflu 75 mg capsules. These instructions are in the current package insert and are also posted separately on the manufacturer's website as information for healthcare professionals
Alternatives to Tamiflu treatment for influenza are described on the CDC website. | Demand Increase for the Drug |
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Hospira Inc. Customer Service: 1-877-946-7747 | 1 mg/mL; 10 mL vial (NDC 0409-4646-01) | Next delivery March Estimated Recovery: 2Q 2013 | Shortage per Manufacturer: Manufacturing delay | Other | Reverified 2/21/2013 |
Papaverine Hydrochloride Injection (Initial Posting Date 12/17/2012)
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| American Regent/Luitpold: 1-800-645-1706 | 30 mg/mL, 2 mL vial (NDC 0517-4002-25) | Company estimates a manufacturing date of 1Q 2013 | Shortage per Manufacturer: Manufacturing delay | Other | Reverified 2/23/2013 |
| 30 mg/mL, 10 mL vial (NDC 00517-4010-01) |
Peginterferon Alpha-2A (Pegasys) Injection-Prefilled Syringes (Initial Posting-3/26/2012)
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Genentech Resource Center: 1-877-436-3683 | 180 mcg/0.5 mL Pegasys Prefilled syringe (PFS) for single use (NDC 0004-0352-39) (NDC 0004-0357-30) | Potential limited availability of the PFS form of 180 mcg/mL Pegasys. The firm anticipates that the potential shortage of the PFS will resolve by end of June 2013. | Shortage per Manufacturer: | Other | Revised 9/24/2012 |
| 180 mcg/0.5 mL Autoinjector for single use (NDC 0004-0365-09) | The firm has adequate supplies | ||||
| 135 mcg/0.5 mL Autoinjector for single use (NDC 0004-0360-09) | The firm has adequate supplies | ||||
| 180 mcg/mL Vial for single use (NDC 0004-0350-09) | The firm has adequate supplies |
Pentamidine isethionate inhalant (NebuPent) (Initial posting-8/27/2012)
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| APP 1-888-386-1300 | 300 mg, SDV (NDC 63323-0877-15) | Available. Check wholesalers for inventory. | Shortage per Manufacturer: | Shortage of an active ingredient | Reverified 2/19/2013 |
Pentamidine isethionate for injection (Pentam 300) (Initial posting-8/27/2012)
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| APP 1-888-386-1300 | 300mg, Lyophilized Powder for Injection (NDC #633230-113-10) | Available. Check wholesalers for inventory. | Shortage per Manufacturer: | Shortage of an active ingredient | Reverified 2/19/2013 |
Phentolamine Mesylate (Regitine) Injection
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Bedford Customer Service: 1-800-562-4797 | Phentolamine mesylate for injection, 5 mg lyophilized vial (NDC 55390-0113-01) | On backorder | Bedford has phentolamine on backorder and the company cannot estimate a release date. Shortage per Manufacturer: | Discontinuation of the manufacture of the drug. | Reverified 5/29/2012 |
Sandoz Inc 1-800-525-8747 | Phentolamine Mesylate Injection 5mg/mL (boxes of 10-1 mL single dose vials) NDC 00781-3028-95 | Please contact your wholesaler or Sandoz Customer Service at 800-525-8747 for ordering information. | Sandoz in conjunction with FDA has initiated temporary importation of phentolamine mesylate injection into the US market to address this shortage. The Sandoz phentolamine mesylate injection 5 mg/mL product contains the same active ingredient, phentolamine mesylate, as the phentolamine mesylate for injection 5 mg vial product approved in the United States. However, there are important differences between the US product and Canadian product that Healthcare providers should be aware of before prescribing and product preparation. Please see the Dear Healthcare Professional Letter (PDF - 260KB) for additional product and supply information. | Other | Reverified 2/11/2013 |
Pilocarpine HCL Opthalmic Gel 4% (Pilopine HS) (Initial posting-6/1/12)
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Alcon Customer Service: 1-800-862-5266 | PILOPINE HS (pilocarpine hydrochloride ophthalmic gel) 4% 4 gm tube: (NDC 0065-0215-35) | Unable to estimate a release date | Updates will be provided as further information becomes available. Shortage per Manufacturer: | Other |
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| American Regent/Luitpold: 1-800-645-1706 | Potassium Acetate Injection, USP 2 mEq/mL | Unavailable | American Regent is currently not releasing Potassium Acetate Injection, USP. | Other | Reverified 2/23/13 |
| 20 mL vial, package of 25 (NDC 00517-2053-25) | |||||
| 50 mL vial, package of 25 (NDC 00517-2450-25) | |||||
| 100 mL Pharmacy Bulk Package, package of 25 (NDC 00517-2400-25) | |||||
Hospira, Inc. | Potassium acetate injection, 2 meq/mL, 20 mL vial (NDC 00409-8183-01) | Next delivery February
Estimated recovery 2Q 2013 | Shortage per manufacturer: manufacturing delay. | Demand increase of the drug; other | Revised 2/21/13 |
| 50 mL vial (NDC 00409-3294-51) | Next delivery mid March
Estimated recovery 2Q 2013 |
Potassium Chloride Injection 2 mEq/mL (Initial posting - 5/15/2012)
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
APP Pharmaceuticals | 2 mEq/mL, 5 mL vials, (NDC 63323-0965-05) | Available. Check wholesalers for inventory. | APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: | Demand increase for the drug. | Reverified 2/19/2013 |
2 mEq/mL, 10 mL vials, (NDC 63323-0965-10) | Available. Check wholesalers for inventory. | ||||
2 mEq/mL, 15 mL vials, (NDC 63323-0965-15) | Unavailable | ||||
2 mEq/mL, 20 mL vials, (NDC 63323-0965-20) | Available. Check wholesalers for inventory. | ||||
2 mEq/mL, 30 mL vials, (NDC 63323-0967-30) | Backordered. No estimated release at this time. | ||||
B. Braun Medical Inc. | 2 mEq/mL, 250 mL bulk package (NDC 00264-1940-20) | Available |
| Revised 10/17/2012 | |
Baxter | 10 mEq/100 mL in sterile water (NDC 00338-0709-48) | Available |
| Demand increase for the drug.
| Reverified 2/28/2013 |
20 mEq/100 mL in sterile water (NDC 00338-0705-48) | Available | ||||
40 mEq/100 mL in sterile water (NDC 00338-0703-48) | Available | ||||
20 mEq/50 mL in sterile water (NDC 00338-0703-41) | Available | ||||
10 mEq/50 mL in sterile water (NDC 00338-0705-41) | Available | ||||
20 mEq/1000 mL in lactated ringers and dextrose 5% (NDC 00338-0811-04) | Available | ||||
20 mEq/1000 mL in 5% dextrose and 0.9% sodium chloride (NDC 00338-0803-04) | Available | ||||
20 mEq/1000 mL in 0.9% sodium chloride (NDC 00338-0691-04) | Available |
| |||
40 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0675-04) | Available | ||||
20 mEq/1000 mL in 5% dextrose (NDC 00338-0683-04) | Available | ||||
40 mEq/1000 mL in 0.9% sodium chloride (NDC 00338-0695-04) | Available | ||||
20 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0671-04) | Available | ||||
20 mEq/500 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0671-03) | Available |
| |||
20 mEq/1000 mL in 0.45% sodium chloride (NDC 00338-0704-34) | Available |
| |||
40 mEq/1000 mL in 5% dextrose and 0.9% sodium chloride (NDC 00338-0807-04) | Available | ||||
20 mEq/500 mL in 5% dextrose and 0.2% sodium chloride (NDC 00338-0663-03) | Available | ||||
20 mEq/1000 mL in 5% dextrose and 0.2% sodium chloride (NDC 00338-0663-04) | Available | ||||
10 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0669-04) | Available | ||||
Hospira, Inc. | 2 mEq/mL; 250 mL bottle (NDC 0409-1513-02) | Next delivery September 2013 | Please check with your wholesaler for available inventory.
Shortage per manufacturer: Available | Demand increase for the drug/Other | Revised 2/21/2013 |
2 mEq/mL; 5 mL vial (NDC 0409-6635-01) | Available | ||||
2 mEq/mL; 15 mL vial (NDC 0409-6636-01) | Next delivery 2Q 2013 Estimated recovery 2Q 2013 | ||||
2 mEq/mL; 20 mL vial (NDC 0409-6651-06) | Available | ||||
2 mEq/mL; 20 mL vial (NDC 0409-6653-05) | Next delivery February | ||||
10 mEq/100 mL (NDC 0409-7074-26) | Available | ||||
10 mEq/50 mL (NDC 00409-7075-14) | Available | ||||
20 mEq/100 mL, | Available | ||||
20 mEq/50 mL | Available | ||||
40 mEq/100 mL | Available | ||||
40 mEq/1000 mL | Next delivery Estimated recovery April | ||||
20 mEq/1000 mL in 0.9% NaCl | Available | ||||
| 20 mEq/1000 mL in 5% dextrose (NDC 00409-7905-09) | Next delivery April Estimated recovery 2Q2013 | ||||
20 mEq/1000 mL in 5% Dex/Lact Ringers (NDC 0409-7119-09) | Available | ||||
10 mEq/500 mL in 5% dex & 0.225% NaCl | Available | ||||
10 mEq/ 500 mL in 5% dex 0.45% NaCl | Available | ||||
20 mEq/1000 mL in 5% dex& 0.225% NaCl | Available | ||||
20 mEq/1000 mL in | Available | ||||
30 mEq/1000 mL in | Available | ||||
40 mEq/1000 mL in | Next delivery March
Estimated recovery April | ||||
10 mEq/1000 mL in 5% dex & 0.45% NaCl | Available | ||||
20 mEq/1000 mL in 5% dex & 0.9% NaCl | Available |
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
Hospira Inc. | 3 mMol/mL, 15 mL vial (NDC 0409-7295-01) | Next delivery late March Estimated recovery 2Q 2013 | Shortage per Manufacturer: | Other | Reverified |
| American Regent/Luitpold 1-800-645-1706 | 3 mMol/mL, 5 mL vial (NDC 00517-2305-25) | Unavailable | Shortage per Manufacturer: American Regent//Luitpold is not manufacturing the 5 mL vials. American Regent//Luitpold is not manufacturing the 15 mL vials. American Regent//Luitpold is not releasing the 50 mL vials | Other | Reverified 2/23/2013 |
| 3 mMol/mL, 15 mL vial (NDC 00517-2315-25) | Unavailable | ||||
| 3 mMol/mL, 50 mL vial (NDC 00517-2350-25) | Unavailable |
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Hospira Inc. Customer Service: 1-877-946-7747 | 100 mg/mL; 10 mL vial (NDC 0409-1902-01) | Available | Please check with your wholesaler for available inventory.
Shortage per Manufacturer: manufacturing delay | Other | Revised 2/21/2013 |
500 mg/mL; 2 mL vial (NDC 0409-1903-01) | Available |
Prochlorperazine Injection (1/30/2012)
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Bedford Customer Service 1-800-562-4797 | 5 mg/mL, 2mL vial, 10 count (NDC 55390-0077-10) | Bedford has both prochlorperazine 5 mg/mL injection presentations on back order and the company cannot estimate a release date. | The 2 mL vials are pending release while the 10 mL vials will not be manufactured until capacity permits. Shortage per Manufacturer:
| Discontinuation of the manufacture of the drug. | |
| 5 mg/mL, 10 mL vial (NDC 55390-0077-01) |
Promethazine Injection (Initial Posting Date) - 2/10/2012
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Hospira, Inc. Customer Service: 1-877-946-7747 | 25 mg/mL 1 mL Carpuject (NDC 0409-2312-31) | Next delivery 2013 | Shortage per Manufacturer: Manufacturing delay | Other | Reverified 2/21/2013 |
| Teva Phamaceuticals 1-800-545-8800 | 25 mg/mL; 1 mL vial (NDC 00703-2191-04) | Teva has all promethazine injection presentations on back order and the company cannot estimate a release date. | Requirements related to complying with good manufacturing practices | Reverified 3/1/2013 | |
| 50 mg/mL; 1 mL vial (NDC 00703-2201-04 | |||||
| West-Ward Pharmaceuticals Customer Service: 1-800-631-2174 | Promethazine 1 mL vial, 25 mg/mL (NDC 0641-0928-25) 1 mL vial, 50 mg/mL (NDC 0641-0929-25) 1 mL ampul, 25mg/mL (NDC 0641-1495-35) 1 mL ampul, 50 mg/mL (NDC 0641-1496-35) | West-Ward is currently experiencing a small backorder situation on the Phenergan 25 mg/mL, 1 mL vial. All other Phenergan and Promethazine codes have available inventory. | West-Ward has accelerated production and will have additional units available for release by the end of January 2013. | Demand increase for the drug. | Reverified 2/11/2013 |
| Phenergan 1 mL vial, 25 mg/mL (NDC 0641-6084-25) 1 mL vial, 50 mg/mL (NDC 0641-6085-25) 1 mL ampul, 25mg/mL (NDC 0641-6082-25) 1 mL ampul, 50 mg/mL (NDC 0641-6083-25) |
Propofol (Diprivan) Injection (Initial Posting Date) - 4/5/2012
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| APP 1-888-386-1300 | Propofol 20 mL (NDC 63323-270-25) | All propofol is on intermittent backorder. | APP is releasing Propofol and Diprivan directly into the channel. Please check wholesalers for inventory. | Demand increase for the drug. | Reverified 2/19/2013 |
| Propofol 50 mL (NDC 63323-270-50) | |||||
| Propofol 100 mL (NDC 63323-270-65) | |||||
| Diprivan 20 mL (NDC 63323-269-20) | |||||
| Diprivan 50 mL (NDC 63323-269-50) | |||||
| Diprivan 100 mL (NDC 63323-269-65) | |||||
| Hospira, Inc. Customer Service: 1-877-946-7747 | 10 mg/mL; 20 mL (NDC 0409-4699-30) | Hospira is allocating to contracted customers and those shipments are in transit and expected to arrive in early to mid February Availability to non-contracted customers is TBD at this time. | Limited allocation of 20 mL vials to contracted customers. Shortage per Manufacturer: manufacturing delay | Other | Revised 2/21/2013 |
| 10 mg/mL; 50 mL (NDC 0409-4699-33) | TBD | ||||
| 10 mg/mL; 100 mL (NDC 0409-4699-24) | Next delivery May | ||||
| APP (Fresenius Kabi) 1-888-386-1300 | Fresenius Propoven 1% 20 mL glass ampule | Importation began July 2012 and will continue until all patient needs are met with approved propofol | APP in conjunction with FDA has initiated temporary importation of Fresenius Propoven 1% (propofol) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 614KB)for additional product and supply information. APP is releasing Fresenius Propoven 1% (propofol) directly into the channel as it becomes available. Shortage per Manufacturer: . | Other | Reverified 1/25/2013 |
Fresenius Propoven 1% 50 mL SD Vial | Importation began July 2012 and will continue until all patient needs are met with approved propofol | ||||
Fresenius Propoven 1% 100 mL SD Vial | Importation began July 2012 and will continue until all patient needs are met with approved propofol | ||||
| Teva Pharmaceuticals 1-800-545-8800 | 10 mg/mL; 20 mL | Teva expects to have limited quantities available April 2013. | Product will be available on allocation through upon receipt | Demand increase for the drug | Revised 3/1/2013 |
10 mg/mL; 100 mL | |||||
Pyridostigmine Bromide (Regnol) Injection
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
Sandoz, Inc.
Customer Service 1-800-525-8747 | 5 mg/mL (NDC 0781-3040-95) | Available | Shortage per Manufacturer: Manufacturing delays and increase in demand | Demand increase for the drug | Revised |
